Antikoagulaatio ja sen kumoaminen

Reversal of antithrombotic agents. (avaa uuden ikkunan)

Bauer KA.

Lähde‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Arkistoitu‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (avaa uuden ikkunan)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (avaa uuden ikkunan)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Lähde‎: J Thromb Haemost 2015;13(10):1790-8.

Arkistoitu‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (avaa uuden ikkunan)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (avaa uuden ikkunan)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Lähde‎: N Engl J Med 2019;380(14):1326-35.

Arkistoitu‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (avaa uuden ikkunan)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (avaa uuden ikkunan)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Lähde‎: N Engl J Med 2016;375(12):1131-41.

Arkistoitu‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (avaa uuden ikkunan)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (avaa uuden ikkunan)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Lähde‎: Circulation 2011;124(14):1573-9.

Arkistoitu‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (avaa uuden ikkunan)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (avaa uuden ikkunan)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Lähde‎: Lancet 2015;385(9982):2077-87.

Arkistoitu‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (avaa uuden ikkunan)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (avaa uuden ikkunan)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Lähde‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Arkistoitu‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (avaa uuden ikkunan)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (avaa uuden ikkunan)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Lähde‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Arkistoitu‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (avaa uuden ikkunan)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (avaa uuden ikkunan)

Levi M, Eerenberg E, Kamphuisen PW.

Lähde‎: J Thromb Haemost 2011;9(9):1705-12.

Arkistoitu‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (avaa uuden ikkunan)

Emergency reversal of warfarin anticoagulation. (avaa uuden ikkunan)

Lin Y, Callum J.

Lähde‎: CMAJ 2010;182(18):2004.

Arkistoitu‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (avaa uuden ikkunan)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (avaa uuden ikkunan)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Lähde‎: Thromb Haemost 2012;108(2):217-24.

Arkistoitu‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (avaa uuden ikkunan)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (avaa uuden ikkunan)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Lähde‎: J Thromb Haemost 2008;6(4):622-31.

Arkistoitu‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (avaa uuden ikkunan)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (avaa uuden ikkunan)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Lähde‎: Blood Adv 2019;3(2):158-67.

Arkistoitu‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (avaa uuden ikkunan)

Idarucizumab for dabigatran reversal. (avaa uuden ikkunan)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Lähde‎: N Engl J Med 2015;373(6):511-20.

Arkistoitu‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (avaa uuden ikkunan)

Idarucizumab for dabigatran reversal - full cohort analysis. (avaa uuden ikkunan)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Lähde‎: N Engl J Med 2017;377(5):431-41.

Arkistoitu‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (avaa uuden ikkunan)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (avaa uuden ikkunan)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Lähde‎: Blood 2003;102(13):4594-9.

Arkistoitu‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (avaa uuden ikkunan)

Role of agents for reversing the effects of target-specific oral anticoagulants. (avaa uuden ikkunan)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Lähde‎: Am J Health Syst Pharm 2017;74(2):54-61.

Arkistoitu‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (avaa uuden ikkunan)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (avaa uuden ikkunan)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Lähde‎: Anesth Analg 2011;113(4):703-10.

Arkistoitu‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (avaa uuden ikkunan)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (avaa uuden ikkunan)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Lähde‎: J Am Coll Cardiol 2017;70(24):3042-67.

Arkistoitu‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (avaa uuden ikkunan)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (avaa uuden ikkunan)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Lähde‎: World Neurosurg 2014;81(1):110-5.

Arkistoitu‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (avaa uuden ikkunan)

Reversal of warfarin-induced hemorrhage in the emergency department. (avaa uuden ikkunan)

Zareh M, Davis A, Henderson S.

Lähde‎: West J Emerg Med 2011;12(4):386-92.

Arkistoitu‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (avaa uuden ikkunan)

TEHOHOITO

Antikoagulaatio ja sen kumoaminen

suomi

Antikoagulaatio ja sen kumoaminen

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Antikoagulaatio ja sen kumoaminen

Reversal of antithrombotic agents. (avaa uuden ikkunan)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (avaa uuden ikkunan)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (avaa uuden ikkunan)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (avaa uuden ikkunan)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (avaa uuden ikkunan)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (avaa uuden ikkunan)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (avaa uuden ikkunan)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (avaa uuden ikkunan)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (avaa uuden ikkunan)

Emergency reversal of warfarin anticoagulation. (avaa uuden ikkunan)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (avaa uuden ikkunan)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (avaa uuden ikkunan)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (avaa uuden ikkunan)

Idarucizumab for dabigatran reversal. (avaa uuden ikkunan)

Idarucizumab for dabigatran reversal - full cohort analysis. (avaa uuden ikkunan)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (avaa uuden ikkunan)

Role of agents for reversing the effects of target-specific oral anticoagulants. (avaa uuden ikkunan)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (avaa uuden ikkunan)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (avaa uuden ikkunan)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (avaa uuden ikkunan)

Reversal of warfarin-induced hemorrhage in the emergency department. (avaa uuden ikkunan)

Ota yhteyttä paikalliseen sairaalayhteyskomiteaan

Tietopaketit terveydenhuollon ammattilaisille

Videot

Antikoagulaatio ja sen kumoaminen

Valitse kielesi

Jaa